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Spermine and spermidine act as neuromodulators upon binding to the extracellular site(s) of various
ionotropic receptors, such as N-methyl-D-aspartate receptors. To gain access to the receptors, polyamines
synthesized in neurons and astrocytes are stored in secretory vesicles and released upon depolarization.
Although vesicular storage is mediated in an ATP-dependent, reserpine-sensitive fashion, the transporter
responsible for this process remains unknown. SLC18B1 is the fourth member of the SLC18 transporter
family, which includes vesicular monoamine transporters and vesicular acetylcholine transporter.
Proteoliposomes containing purified human SLC18B1 protein actively transport spermine and spermidine
by exchange of H1. SLC18B1 protein is predominantly expressed in the hippocampus and is associated with
vesicles in astrocytes. SLC18B1 gene knockdown decreased both SLC18B1 protein and spermine/
spermidine contents in astrocytes. These results indicated that SLC18B1 encodes a vesicular polyamine
transporter (VPAT).
T
he polyamines, spermine (Spm) and spermidine (Spd), and their precursor, putrescine, are low molecular
weight organic polycations that are synthesized from arginine andmethionine and play essential roles in cell
growth and differentiation in practically all living organisms1–4. Moreover, in the central nervous system,
Spm and Spd play significant roles as second messengers in neurotransmission4–6. In neurons, intracellular Spm
and Spd exhibit strong inward rectification upon binding to various ion channels, such as potassium channels,
olfactory cyclic nucleotide-gated channels, and voltage-gated sodium channels, which may be involved in neu-
rodegenerative diseases, such as Huntington’s disease7–11. Extracellular Spm and Spd potentiate or block the
N-methyl-D-aspartate (NMDA) receptor current upon binding to the specific binding sites at low and high
concentrations, respectively5,6,12. As positive modulation of NMDA receptors may lead to enhanced Ca21 entry,
extracellular Spm and Spd may cause excitotoxicity under some pathological conditions5,6. Extracellular poly-
amines also potentiate the kainate receptor and the transient receptor potential cation channel subfamily V
member 1 (TrpV1 or capsaicin receptor) and block the AMPA receptor upon binding to their specific sites13–16.
Thus, polyamines interact with neurons intracellularly and extracellularly, and profoundlymodulate neurotrans-
mission, affecting higher order brain functions, including synaptic plasticity, and have been implicated in
neuropathological disorders17. To understand the physiological and pathological relevance of polyamine-
mediated neuromodulation, it is important to elucidate the signaling pathways and mechanisms by which
polyamines gain access to the target receptors.
The brain contains relatively high concentrations of polyamines18,19. Spm- and Spd-like immunoreactivities are
predominantly present in glial cells, particularly astrocytes. Much lower levels of immunoreactivity are observed in
neurons, except that prominent localization is observed in some specific neurons, such as neurosecretory neu-
rons20,21. The polyamine synthesizing enzymes, ornithine decarboxylase and spermidine synthase, are primarily
present in neurons and neuropil rather than glial cells22–24. Furthermore, it has been reported that intrastriatal
infusion of NMDA causes rapid marked increases in extracellular Spm and Spd levels in the brain25. Ca21-
dependent Spm and Spd release from brain slices and synaptosomes were also observed upon K1 stimulation26,27.
The released polyamines may be sequestered through high-affinity polyamine uptake in neurons and astrocytes27,28.
Moreover, the membrane fraction (P2 fraction) from rat brain exhibits ATP-dependent uptake of Spm and Spd,
which was sensitive to proton conductor and reserpine27. In analogy to chemical transmission by the classical
neurotransmitters, such as glutamate and monoamines, it is therefore tempting to speculate that Spm and Spd are
synthesized de novo, stored intracellularly, and exocytosed from neurons and/or astrocytes to modulate the
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receptors upon binding extracellularly. However, transporters
involved in vesicular storage of polyamines have yet to be identified.
Vesicular neurotransmitter transporters are active transporters of
neurotransmitters and are responsible for their vesicular storage and
subsequent exocytosis29,30. Six classes of transporter have been iden-
tified to date: vesicular monoamine transporter (VMAT), vesicular
acetylcholine transporter (VAChT), vesicular GABA transporter
(VGAT), vesicular glutamate transporter (VGLUT), vesicular nuc-
leotide transporter (VNUT), and vesicular aspartate transporter
(VEAT)29,30. Identification of vesicular polyamine transporters, if
present, may help to identify polyamine-secreting cells and storage
vesicles for Spm and Spd, and ultimately to define the signaling
cascade for polyamines. Among the above transporters, VMATs
and VAChT belong to the SLC18 family and transport monoamines.
Recently, a novel gene belonging to the SLC18 family, SLC18B1
(HGNC:21573), was reported although its function is not known31
(Supplementary Fig. 1).We postulated that this proteinmay function
as a vesicular polyamine transporter. Here, we present evidence that
the SLC18B1 protein fulfills the requirements for vesicular storage of
Spm and Spd in the brain.
Results
SLC18B1 protein is an H1/polyamine antiporter. To test the
working hypothesis that SLC18B1 encodes a vesicular polyamine
transporter, the human SLC18B1 protein was expressed in High
Five cells, solubilized from the membranes with detergent, and
purified by Ni-NTA column chromatography. The purified protein
fraction contained a major polypeptide with apparent molecular
mass of 48 kDa on sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) after staining with Coomassie
Brilliant Blue (Fig. 1a, left). The identity of the polypeptide as the
SLC18B1 protein was confirmed by western blotting with anti-
human SLC18B1 protein antibody (Fig. 1a, right). The purified,
heterologously expressed SLC18B1 protein was co-reconstituted
into liposomes with bacterial F-ATPase, and the uptake of
radiolabeled polyamine was measured. Upon addition of ATP, the
F-ATPase hydrolyzes ATP and pumps protons into the
proteoliposomes, thereby establishing an electrochemical gradient
of protons across the membrane29,30. Consequently, the
proteoliposomes took up radiolabeled Spm in a manner that was
dependent on time, ATP, and dose with Km and Vmax values of
94 mM and 8.6 nmol/min/mg protein, respectively (Figs. 1b and c).
The uptake was significantly reduced in the absence of ATP or in the
absence of SLC18B1 protein (Fig. 1b). The ATP-dependent uptake of
Spm was also significantly reduced when nigericin was included in
the assay medium containing K1, whereas valinomycin had no
inhibitory effect. Addition of both nigericin and valinomycin
concomitantly reduced uptake of Spm to that observed in the
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Figure 1 | SLC18B1 protein is an H1-coupled polyamine transporter. (a) Purification of heterologously expressed human SLC18B1 protein. (left)
Purified fraction (10 mg of protein) was analyzed by SDS-PAGE (11% gel) and visualized by staining with Coomassie Brilliant Blue. (right) A duplicate gel
was analyzed by western blotting with anti-SLC18B1 antibody. The position of SLC18B1 protein is indicated by an arrow. (b) Time course of ATP-
dependent radiolabeled Spm uptake by proteoliposomes containing reconstituted human SLC18B1 protein and bacterial F-ATPase. The reaction was
started by adding radiolabeled Spm to a final concentration of 10 mM in the presence (filled circles) or absence (open circles) of 5 mMATP. Spm uptake
by proteoliposomes lacking SLC18B1 protein is also shown (open triangles). (c) Dose dependence of ATP-dependent Spm uptake by proteoliposomes
containing reconstituted SLC18B1 protein and bacterial F-ATPase after 1 minute. A Lineweaver–Burk plot is shown in the inset. (d) The effects of
ionophores on Spm uptake by proteoliposomes containing reconstituted SLC18B1 protein and bacterial F-ATPase. Ionophores were added at 2 mM to
the reaction mixture in the presence of ATP, and the Spm uptake after 5 minutes is shown. (e) Spm uptake by the proteoliposomes containing
reconstituted SLC18B1 protein was assayed by the pH jumpmethod (acidic inside) as described in theMethods section. (f) Effects ofmembrane potential
on Spmuptake. Proteoliposomes were reconstituted in the presence of 0.15 MNaCl and assayed in the reactionmixture containing 0.15 MKCl. (g) Time
course of Spd uptake at 500 mM was measured as above instead of radiolabeled Spm at 10 mM. (h) Dose dependence of ATP-dependent Spd uptake by
proteoliposomes containing reconstituted SLC18B1 protein and bacterial F-ATPase after 1 minute. A Lineweaver–Burk plot is shown in the inset. (i) The
effects of ionophores on Spd uptake were examined as shown in Fig. 2d. (j) Spd uptake by proteoliposomes containing only SLC18B1 protein was
examined as shown in Fig. 2e. (k) Effects of membrane potential on Spd uptake. Data are means 6 SE; n 5 3–6.
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presence of nigericin alone (Fig. 1d). To confirm that DpH was the
driving force, we prepared proteoliposomes containing only
SLC18B1 protein as a protein source and examined Spm uptake.
Imposing an artificial DpH gradient (inside acidic) by the pH jump
procedure facilitated Spm uptake (Fig. 1e), while Dy produced by
valinomycin-mediated K1 diffusion potential did not (Fig. 1f). The
proteoliposomes also took up radiolabeled Spd with Km and Vmax
values of 4.2 mM and 170 nmol/min/mg protein, respectively, and
with similar ionophore sensitivities (Figs. 1g–i). Imposing an
artificial DpH (inside acidic) by the pH jump procedure also
facilitated Spd uptake (Fig. 1j and k).
Pharmacology of SLC18B1 protein. Subsequently, we investigated
the effects of reserpine and tetrabenazine, inhibitors for VMATs32,33,
and vesamicol, an inhibitor of VAChT34, on SLC18B1-mediated Spm
uptake. Furthermore, we compared the effects of these compounds
on VMAT2 and VAChT under analogous conditions after
purification and co-reconstitution with F-ATPase in liposomes
(Supplementary Fig. 2). The results indicated that both reserpine
and tetrabenazine inhibited ATP-dependent Spm uptake by
SLC18B1 but their inhibitory potencies were weak compared with
those for VMAT2 and VAChT (Figs. 2a–c). In contrast, vesamicol
specifically inhibited VAChT-mediated acetylcholine transport and
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Figure 2 | Pharmacology and substrate specificity of SLC18B1 protein, VMAT2, and VAChT. (a–c) The effects of reserpine, tetrabenazine, and
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minutes. (d) ATP-dependent uptake of 10 mM Spm, 100 mM Spd, 10 mM serotonin, or 10 mM acetylcholine by SLC18B1 protein, VMAT2, and VAChT
after 5 minutes. The values were corrected by subtracting the values in the absence of ATP. Control Spm, Spd, serotonin, and acetylcholine activities
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uptake after 1 minute. SLC18B1 protein-mediated uptake of 10 mM Spm and 500 mM Spd was measured in the absence or presence of the listed
compounds at 1 mM and 5 mM, respectively. Data are means 6 SE; n 5 3–6.
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hardly affected the activities of SLC18B1 protein or VMAT2
(Figs. 2a–c).
Polyamine transport is a unique property of SLC18B1 protein.
VMAT and VAChT are polyspecific in nature. In addition to
typical substrates such as serotonin and acetylcholine, they also
transport various other compounds, such as ethidium and
tetraphenylphosphonium35,36. Before it could be concluded that
SLC18B1 protein is a polyamine transporter, it was therefore
necessary to confirm that VMATs and VAChT do not transport
polyamines. As shown in Fig. 2d, we found that neither VMAT2
nor VAChT transport Spd and Spm. All three transporters tested
took up serotonin to a similar extent, indicating that serotonin is a
mutual transport substrate in the SLC18 family. In contrast, no
acetylcholine uptake was observed with SLC18B1 protein and
VMAT2.
To strengthen the evidence regarding the polyspecific nature of
SLC18B1 protein, we investigated its substrate specificity by cis-
inhibition. As shown in Fig. 2e, the ATP-dependent uptake of radi-
olabeled Spm by SLC18B1 protein was inhibited by the addition of
cold Spm, serotonin, and histamine to some extent, while putrescine,
ornithine, dopamine, and acetylcholine had little effect. Both agma-
tine and noradrenaline produced slightly stimulatory effects. To our
surprise, unlabeled excess Spd did not inhibit uptake of radiolabeled
Spm but was stimulatory, even though the SLC18B1 protein trans-
ported Spd (Fig. 2e). Conversely, unlabeled excess Spm also did not
inhibit the uptake of radiolabeled Spd, but had a stimulatory effect, as
was the case with Spd and Spm transport (Fig. 2e). These results
indicated that for SLC18B1 protein-mediated polyamine transport,
the degree of cis-inhibition is not always consistent with transport.
SLC18B1 protein was suggested to possess at least two different
substrate binding sites for Spm and Spd: one prefers Spm and the
other prefers Spd. Serotonin and histamine may share these two
binding sites.
Localization of SLC18B1 protein. We analyzed tissue-dependent
expression of human SLC18B1 by quantitative PCR. The results
indicated that the SLC18B1 gene is widely expressed in various
organs, including the lung, placenta, adrenal gland, liver, and brain
(Fig. 3). A similar expression profile was obtained inmice, which was
in good agreement with a previous report31.
Then, we examined the localization of SLC18B1 protein in the rat
brain using a polyclonal antibody specific to mouse SLC18B1 pro-
tein. The immunological specificity of the antibody was verified
(Supplementary Fig. 3). The antibody recognized a 53-kDa protein
in the P2 fraction of brain hippocampal homogenate. No immuno-
reactivity was observed when the antibody was preabsorbed with
purified SLC18B1 protein (Fig. 4a). The antibodies also immunos-
tained rat brain sections and showed strong immunoreactivity
throughout brain tissue, particularly the hippocampus, cortex, and
cerebellum (Fig. 4b and Supplementary Fig. 4). The immune signal
for the SLC18B1 protein in the hippocampus was primarily coloca-
lized with GFAP and not with NeuN or neurofilaments, suggesting
that SLC18B1 protein is expressed in astrocytes and is roughly colo-
calized with synaptophysin, suggesting that some SLC18B1 protein is
also associated with synaptic vesicles (Fig. 4c). In cultured neurons,
SLC18B1 protein was partly colocalized with synaptophysin
(Supplementary Fig. 5). However, it was also localized in other
organelles.
In cultured embryonic rat astrocytes, SLC18B1 protein was
observed as a polypeptide with an apparent molecular mass of
53 kDa (Fig. 5a). Double labeling immunofluorescence microscopy
showed that SLC18B1 immunoreactivity was present in particulate
structures throughout the cells, which were roughly colocalized with
VAMP2, a marker for secretory vesicles, but not with chromogranin
A (CgA), a marker for dense granules, or with GM130, EEA1, mar-
kers of the Golgi apparatus and early endosome and PDI, a marker
for endoplasmic reticulum, respectively (Fig. 5b and c). We further
characterized the SLC18B1-containing organelles by sucrose density
gradient centrifugation after homogenization of astrocytes. VAMP2,
a secretory granule marker, and V-ATPase immunoreactivity were
observed in fractions 1–3 of higher density and fractions 6–9 of lower
density, whereas cathepsin D, a lysosome marker, was located in
fractions 1–2 of higher density. As expected, SLC18B1 protein was
mainly present in fractions 4–10, whereas secretogranin II as well as
CgA, both markers of dense granules, were located in fractions 1–2
and 1–3, respectively, with higher density (Fig. 5d).
Finally, we investigated whether SLC18B1 protein is responsible
for the vesicular storage of polyamines. As cultured astrocytes pos-
sess appreciable amounts of Spm and Spd, we attempted to deter-
mine the localization of endogenous Spm and Spd in cultured
astrocytes. RNAi-mediated knockdown of the SLC18B1 gene
expression in cultured astrocytes decreased the levels of SLC18B1
mRNA as determined by real-time PCR and the respective protein
levels as shown by western blotting and immunohistochemistry
(Figs. 6a–c). As shown in Fig. 6c, immunological counterparts of
Spm and Spd showed a punctate distribution throughout astrocytes.
In agreement with the decrease in mRNA and protein levels (Fig. 6a
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and 6b), the treatment also decreased immunological counterparts of
Spm and Spd, suggesting that SLC18B1 protein is responsible for the
vesicular storage of polyamines (Fig. 6c).
Discussion
In the present study, we explored and identified the transporter that
is responsible for vesicular storage of Spm and Spd in mammals.
SLC18B1 encodes vesicular polyamine transporter. Biochemical
studies with the heterologously expressed purified protein clearly
demonstrated that the SLC18B1 protein, a novel isoform of the
VMAT family, acts as an H1/Spm or Spd antiporter. The transport
characteristics are similar to the ATP-dependent Spm and Spd
uptake observed in crude synaptic vesicles27. These characteristics
include the kinetic parameters, driving force, and effects of
reserpine, basic amino acids, and amines27. Among the members of
the SLC18 family, polyamine transport is a unique property of the
SLC18B1 protein. Furthermore, as discussed in detail later, the
SLC18B1 protein is localized to small vesicles in astrocytes and
neurons. Taken together, the observations indicated that the
SLC18B1 protein functions as a vesicular polyamine transporter
(VPAT) responsible for vesicular storage of Spm and Spd. It is
noteworthy that this is the first example of a vesicular polyamine
transporter in mammals reported to date.
It has been shown that acidic organelles from CHO cells accu-
mulate polyamines in a vacuolar ATPase-dependent manner37.
Furthermore, insulin granules of islet b cells and mast cell granules
are also known to accumulate polyamines38,39. Preliminary experi-
ments indicated that VPAT is expressed in islets and mast cells,
supporting our conclusion.
Structural and functional properties of VPAT.Mammalian VPAT
is completely different from known polyamine transporters found in
bacteria, yeast, and plants40,41. Among the structural aspects deduced
from its primary amino acid sequence, a notable difference between
VPAT and other SLC18 members is the lack of a large luminal loop
between transmembrane domain (TMD) 1 and TMD2, which
suggests a functional difference31. It is generally accepted that
conserved charged residues in transmembrane domains play
critical functional roles in many transporters. In the case of rat
VMAT2, replacement of Asp33, Lys139, Asp400, or Asp427
markedly decreased serotonin transport activity42,43. These residues
are located in the first, second, tenth, and eleventh TMD, and are
conserved in VMATs and VAChT. Similar results were reported for
rat VMAT1 and VAChT44–46. The presence of these charged amino
acid residues that are important for activity in VMATs and VAChT
indicated that these transporters share the same mechanism for
transport. In contrast, these four amino acid residues are not
conserved in VPAT31. VPAT has five charged amino acid residues
in the TMDs, i.e., Glu83 in TMD2, Arg137 and Asp140 in TMD4,
Asp255 in TMD7, and Glu356 in TMD10. Among these amino acid
residues, Arg137 and Asp255 are conserved in all SLC18 members.
Rat VAChT still retained transport activity if Glu309 was replaced
with Gln (corresponding to Asp255 in VPAT), indicating that this
residue does not have a critical role in VAChT47. Furthermore, Spm
uptake by VPAT was not sensitive to vesamicol, an inhibitor of
VAChT, but was moderately sensitive to the VMAT inhibitors
reserpine and tetrabenazine. The amino acid residues responsible
for inhibition by these drugs in VMAT and VAChT are not
present in VPAT. For example, Phe335 is important for vesamicol
binding to rat VAChT; the corresponding residue in VPAT is
alanine48. Based on conservation of catalytically important
residues, we suggest that the transport mechanism of VPAT is
somewhat different from those of VMATs and VAChT although
VPAT and VMAT2 share similar inhibitor sensitivity.
All transporters belonging to the SLC18 family can recognize
monoamines as substrates but only VPAT can recognize monoa-
mines, diamines, triamines, and tetraamines as substrates. Spm
and Spd seem to have separate binding sites as VPAT transports
Spm and Spd irrespective of the presence of the other polyamine.
Furthermore, it is noteworthy that histamine and serotonin may
a
c
100
75
50
37
kDa
b
SLC18B1 GFAP Merge
SLC18B1 NeuN Merge
SLC18B1 Synaptophysin Merge
SLC18B1 Neurofilament Merge
500 µm
500 µm
SLC18B1 Control
Figure 4 | Expression and localization of SLC18B1 protein in the rat
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into 10 fractions from the bottom. Each fraction (50 mL) was solubilized
with SDS sample buffer and immunoblotted with antibodies against
SLC18B1, VAMP2, secretogranin II, chromogranin A (CgA), V-ATPase
subunit A, and cathepsin D.
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bind to both binding site(s), as histamine inhibits transport of Spm
and Spd to a similar extent (Fig. 3e). Inhibition of polyamine trans-
port by histamine suggests that VPAT transports histamine and acts
as a vesicular histamine transporter. Histamine granules inmast cells
contain Spm and Spd, supporting this suggestion39. However, it is
accepted that VMAT2 transports histamine and its genetic deletion
results in the total loss of vesicular histamine in mast cells, indicating
that VMAT2 is responsible for vesicular accumulation and release of
histamine49. Further studies are underway in our laboratory to exam-
ine whether VPAT is expressed in mast cells, and if so, whether
VPAT is involved in vesicular storage of histamine, Spm, and Spd
in mast cells.
Through systematic analyses of the transport properties of VPAT,
VMAT2, andVAChT, we found thatVAChT transports serotonin. It
has long been believed that VAChT specifically transports acet-
ylcholine32,35. However, VAChT was shown to be polyspecific in
nature36. The results of the present study further support this con-
clusion. Taken together, the present results indicate that all members
of the SLC18 family are polyspecific, and that VPAT is unique
because it possesses transport ability for divalent and trivalent
amines. The possible contributions of VAChT and VPAT to seroto-
nergic chemical transmission are interesting topics for further study,
and reevaluation of classical monoaminergic chemical transmission
will be necessary.
Spm and Spd as possible neuro/gliotransmitters. The identi-
fication of VPAT has helped to partially determine the novel
signaling pathway(s) that polyamines undergo:vesicular storage,
exocytosis, followed by binding to target receptors in postsynaptic
membranes.
It should be noted that glia, particularly astrocytes, control syn-
aptic plasticity and are involved in the regulation of higher brain
functions, such as learning andmemory50. D-Serine plays an essential
role in these regulatory processes: D-serine is stored in synaptic-like
microvesicles (SLMV), and vesicular D-serine is released in a Ca21-
dependent manner from astrocytes upon AMPA-type receptor
stimulation and acts as a co-agonist of NMDA receptors upon bind-
ing to the specific site50. Moreover, vesicular D-serine transport activ-
ity was recently detected in astrocytic SLMV, which is energetically
coupled with vacuolar H1-ATPase and actually behaves as an H1/D-
serine antiporter51. Thus, the physiological relevance and themode of
action of D-serine seem to be very similar to those of Spm and Spd
shown here. It is possible that postsynaptic stimulation triggers the
polyaminergic and D-serinergic responses of astrocytes, leading to
enhanced gliotransmission.
In conclusion, a seventh vesicular neurotransmitter transporter,
VPAT, which is responsible for vesicular storage of polyamines, has
been identified. Through identification and initial characterization of
VPAT, the mechanism by which polyamines are stored and released
from polyamine-secreting cells was partially clarified.
Methods
cDNA. cDNA of human SLC18B1 (Accession No. NM052831) and mouse SLC18B1
(Accession No. NM183116) were cloned by PCR.
Expression of the SLC18B1 gene.Human or mouse total RNAs from several tissues
were purchased from Clontech. cDNA was generated from total RNA using a reverse
transcriptase kit (Toyobo) using 1 mg of total RNA as the template. The resulting
cDNA pool was used for real-time PCR. Real-time PCR was carried out with
400 nmol/L of specific forward and reverse primers and 5 units/mL of SYBR Premix
Ex Taq (TaKaRa). Thirty-five cycles of amplification were performed with
denaturation at 95uC for 15 s and annealing/extension at 60uC for 30 s. The primer
sets used were as follows: for detection of human SLC18B1, 59-ctggcatccttggtatttggaa-
39, 59-caataaatactggcccatctggaa-39; for mouse SLC18B1, 59-tcgagtgggcagcagctatg-39,
59-ccagagctctcaaggctaggtgtc-39; and for rat SLC18B1, 59-acggaataagtacgctgggacttg-39,
59-tagctgctgcccactcgaaac-39. The expression of SLC18B1 was evaluated relative to the
mRNA expression of the housekeeping gene, glyceraldehyde 3-phosphate
dehydrogenase (G3PDH).
Purification of SLC18B1 protein. Recombinant baculovirus containing human
SLC18B1 cDNAwas constructed using the Bac-to-Bac baculovirus expression system
(Invitrogen) according to the manufacturer’s protocol. Human SLC18B1 cDNA was
amplified by PCR using the primers 59-caccatggaggcgctgggtgac-39 and 59-
actaggtttcattaggcaagag-39. High Five cells were infected by recombinant
baculoviruses at a multiplicity of infection (MOI) of 1 and cultured for a further
48 hours.
The cells (1–2 3 108) were suspended in a buffer containing 20 mM Tris-HCl (pH
8.0), 0.1 M sodium acetate, 10% glycerol, 0.5 mM dithiothreitol, 10 mg/mL pepstatin
A, and 10 mg/mL leupeptin, and disrupted by sonication with a TOMY UD200 tip
sonifier. Cell lysates were centrifuged at 700 3 g for 10 minutes to remove debris and
the resultant supernatant was centrifuged at 160000 3 g for 1 hour. The pellet
(membrane fraction) was suspended in buffer containing 20 mM MOPS-Tris (pH
7.0), 10% glycerol, 10 mg/mL pepstatin A, and 10 mg/mL leupeptin at approximately
1.5 mg protein/mL, and was solubilized with 2% octyl glucoside. After centrifugation
at 260000 3 g for 30 minutes, the supernatant was taken and applied to 1 mL of Ni-
NTA Superflow resin (Qiagen). After incubation for 4 hours at 4uC, the resin was
washed with 20 mL of 20 mMMOPS-Tris (pH 7.0), 5 mM imidazole, 20% glycerol,
and 1% octyl glucoside52. SLC18B1 protein was eluted from the resin with 3 mL of the
same buffer containing 80 mM imidazole and could be stored at 280uC without loss
of activity for at least a few months.
Reconstitution of SLC18B1 protein. Reconstitution of purified SLC18B1 protein
into liposomes was carried out by the freeze-thaw method as described53. Briefly,
40 mg of SLC18B1 protein was mixed with 90 mg of FoF1-ATPase and asolectin
liposomes (0.5 mg lipid), frozen at 280uC, and left at this temperature for at least 15
minutes. The mixture was thawed quickly by holding the sample tube in the hands
and diluted 60-fold with reconstitution buffer containing 20 mM MOPS-Tris (pH
7.0), 0.1 M potassium chloride, and 5 mM magnesium acetate. Reconstituted
proteoliposomes were sedimented by centrifugation at 200000 3 g for 1 hour at 4uC,
suspended in 0.2 mL of 20 mM MOPS-Tris (pH 7.0) containing 0.1 M potassium
chloride and 5 mM magnesium acetate, and used within 1 day of preparation.
Asolectin liposomes were prepared as follows: soybean lecithin (20 mg; Sigma Type
IIS) was suspended in 2 mL of 20 mM MOPS-NaOH (pH 7.0) containing 1 mM
dithiothreitol. The mixture was sonicated in a bath-type sonicator until clear, divided
into small aliquots, and stored at 280uC until use.
Expression, purification, and reconstitution of VMAT2 and VAChT. The cDNAs
of rat VMAT2 and human VAChT were described previously54,55. VMAT2 and
VAChT protein fused with hydrophilic Escherichia coli protein YbeL (b-VAChT-b)
were expressed in insect cells and E. coli C43 (DE3) cells, respectively. They were
purified, reconstituted into proteoliposomes, and assayed in a manner analogous to
that described for human SLC18B1 above54,55. The apparently higher molecular
weight of b-VAChT-b on SDS-PAGE (,80 kDa) was due to fusion with YbeL
(Supplementary Fig. 3).
Uptake of neurotransmitters by proteoliposomes. Transport assays were
performed as described previously54,55. Proteoliposomes (1.5 mg total protein/assay)
were suspended in 20 mM MOPS-Tris (pH 7.0), 5 mM magnesium acetate, and
0.1 M potassium chloride, and then incubated for 1 minute at 27uC. ATP was added
to a final concentration of 5 mM and the mixture was incubated for a further 1
minute. The assay was initiated by addition of 10 mM [ 3H] Spm (0.5 MBq/mmol),
100 mM [ 3H] Spd (0.5 MBq/mmol), 10 mM [ 3H] serotonin (0.5 MBq/mmol), or
10 mM [ 3H] acetylcholine (0.5 MBq/mmol); 130 mL aliquots were taken at the times
indicated and centrifuged through a Sephadex G-50 (fine) spin column at 7603 g for
2minutes. Radioactivity in the eluate wasmeasured with a liquid scintillation counter
(PerkinElmer).
Hippocampal neuron and astrocyte cell culture. Hippocampal cultures were
obtained from embryonic Wistar rats (E17) and C57BL/6 mice (E17). Briefly, after
dissection, the hippocampi were dissociated by treatment with trypsin (0.25%w/v for
15 minutes at 37uC). Astrocyte cultures were maintained in Dulbecco’s modified
Eagle’s medium containing 10% fetal bovine serum in an atmosphere of 5%CO2/95%
air at 37uC and grown to confluence. The medium was changed every 3–4 days. After
reaching confluency, the cells were subcultured and used in experiments during the
following 3 days. Neuron cultures were plated on poly-L-lysine and laminin-coated
cell culture dishes and grown in Neurobasal medium (Invitrogen) containing B27
supplement (Invitrogen). The culture medium was exchanged every 2–3 days.
Experiments were performed between 18 and 21 days in culture.
Antibodies. Site-specific polyclonal antibodies against human and mouse SLC18B1
were prepared by repeatedly injecting GST-fusion polypeptides encoding Met1–
Thr70 of human SLC18B1 and Glu429–Thr457 of mouse SLC18B1 into rabbits,
respectively. Subunit A of V-ATPase rabbit polyclonal antibody and anti-VMAT2
rabbit polyclonal antibody against synthetic peptide (Cys-Pro-Ile-Gly-Glu-Asp-Glu-
Glu-Ser-Glu-Ser-Asp) prepared in-house were determined previously56. The
following primary antibodies were purchased from the commercial sources indicated:
anti-GFAP mouse monoclonal antibody (Thermo Fisher Scientific), anti-
synaptophysin mouse monoclonal antibody (Progen), anti-160-kDa Neurofilament
medium mouse monoclonal antibody (Abcam), anti-PDI mouse monoclonal
antibody (Abcam), anti-NeuN mouse monoclonal antibody (Millipore), anti-
VAMP2 mouse monoclonal antibody (Synaptic System), anti-CgA mouse
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monoclonal antibody (Affinity BioReagents), anti-GM130 mouse monoclonal
antibody (BD Biosciences), anti-EEA1 mouse monoclonal antibody (BD
Biosciences), anti-secretogranin II mouse monoclonal antibody (Abcam), anti-
cathepsin D goat polyclonal antibody (Santa Cruz Biotechnology), anti-Spm/Spd
rabbit polyclonal antibody (Novus Biologicals), and anti-VAChT rabbit polyclonal
antibody (Abcam).
Immunohistochemistry. Indirect immunofluorescence microscopy was performed
as described57. Brain samples were obtained from male Wistar rats or C57BL/6 mice
perfused intracardially with 4% (w/v) paraformaldehyde in 0.1 M phosphate buffer
(pH 7.4). Cultured cells on poly-L-lysine-coated coverslips were fixed with 4%
paraformaldehyde in PBS for 30 minutes. The primary antibody against mouse
SLC18B1 protein was diluted 15200 (v/v) with PBS containing 0.5% (w/v) BSA and
the sample was incubated for 1 hour at room temperature. Washing steps and
secondary antibody treatment were performed as described57. The specimens were
observed either under an Olympus FV300 confocal laser microscope (Olympus) or
BIOZERO (Keyence).
For immunoperoxidase labeling, coronal sections of the mouse brain 30 mm thick
were cut on a freezing microtome. Immunoperoxidase staining was performed on
free-floating sections according to standard immunoperoxidase protocols as
described58. The sections were photographed with BIOZERO (Keyence) and merged
to obtain whole brain images using image-joint software BZ-Analyzer (Keyence).
RNAi. HiPerFect transfection reagent (Qiagen) was used for transfection of 10 nM
AllStars negative control siRNA or rat SLC18B1 siRNA (Qiagen, SI01708707).
SLC18B1 expression was assayed after 48 hours incubation.
Miscellaneous procedures.Transport assay by the synaptic vesicles, SDS-PAGE, and
western blotting were performed as described59. Protein concentration was assayed
using BSA as a standard60.
Data analysis. All numerical values are shown as the means 6 SEM; n 5 3–6, unless
otherwise specified. Statistical significance was determined by Student’s t test.
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